{"brief_title": "Efficacy/Safety of Ecraprost in Lipid Emulsion for Treatment of Critical Leg Ischemia Due to Peripheral Arterial Disease", "brief_summary": "Ecraprost in lipid emulsion is being developed for the treatment of Critical leg ischemia (CLI), which is the most severe form of peripheral arterial disease (PAD); This trial is designed to assess the efficacy and safety of the drug in the treatment of CLI.", "condition": "Peripheral Vascular Disease", "intervention_type": "Drug", "intervention_name": "Ecraprost in lipid emulsion", "criteria": "Inclusion Criteria: - Critical leg ischemia (CLI) defined as distal extremity pain at rest, or peripheral ischemic ulcer(s), with severe hemodynamic impairment as diagnosed by ankle systolic pressure, toe systolic pressure or TcPO2 - Subjects will already be scheduled to receive a revascularization procedure (e.g., by-pass graft, endovascular procedure, etc.) involving a distal target artery below the knee joint (e.g., below the knee joint popliteal, anterior/posterior tibial, peroneal, plantar, pedal, etc.) as part of their normal standard of care. Exclusion Criteria: - Subjects with a previous major amputation (at or above ankle) - Subjects with end stage renal disease (ESRD) defined as significant renal dysfunction evidenced by estimated creatinine clearance of < 20 cc/min, or receiving chronic hemodialysis therapy.", "gender": "All", "minimum_age": "40 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00059657.xml"}